AHA 2025 guidelines for acute coronary syndromes: latest evidence and comparison with ESC guidelines

Abstract

The recently released 2025 ACC/AHA guidelines for the management of acute coronary syndromes (ACS) arise from the need to unify and update all contemporary evidence regarding the diagnosis, risk stratification, and treatment of ACS. The document addresses both out-of-hospital management and in-hospital care, providing dedicated flowcharts for patients with ST-segment elevation myocardial infarction (STEMI)—where the primary goal is immediate reperfusion— and for those with non–ST-segment elevation ACS (NSTE-ACS), in whom therapeutic decisions depend on allocation into four distinct risk categories based on clinical presentation, hemodynamic status, and arrhythmic profile, supported by validated prognostic scores. The risk class determines the optimal timing of the invasive strategy. A central role is attributed to antithrombotic therapy, encompassing both antiplatelet and anticoagulant agents, with strong emphasis on an individualized, patient-tailored balance between ischemic and bleeding risks to guide drug selection and treatment duration. Guideline further addresses secondary prevention, highlighting lipid-lowering strategies and evidence-based use of cardioprotective drugs. Dedicated sections are devoted to the management of mechanical and electrical complications, cardiogenic shock, and advanced catheterization laboratory strategies, including complete revascularization in multivessel disease. In our editorial, we provide a comparative analysis with the 2023 ESC Guidelines on ACS, underscoring that while the core principles remain largely concordant, subtle differences in clinical approach persist between the American and European documents.